Anti-Fibrinolytic Drugs - Ireland

The projected revenue for the Anti-Fibrinolytic Drugs market in Ireland is estimated to reach US$37.32m in 2024.
It is expected to exhibit a Compound Annual Growth Rate (CAGR 2024-2029) of 4.32%, leading to a market volume of US$46.11m by 2029.
When comparing globally, United States is anticipated to generate the highest revenue of US$9.86bn in 2024.
Ireland's pharmaceutical industry is experiencing a surge in demand for anti-fibrinolytic drugs, driven by advancements in medical research and an aging population.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Ireland has been steadily growing over the past few years.

Customer preferences: One of the driving factors behind this growth is the increasing demand for these drugs in the healthcare industry. Anti-fibrinolytic drugs are used to prevent excessive bleeding in patients undergoing surgery or those with bleeding disorders. With an aging population and an increase in the number of surgeries being performed, the demand for these drugs is expected to continue to rise.

Trends in the market: In Ireland, there has been a trend towards the use of more advanced and effective anti-fibrinolytic drugs. Newer drugs such as tranexamic acid and aprotinin have been gaining popularity due to their higher efficacy and lower risk of side effects compared to older drugs such as aminocaproic acid. Additionally, there has been a shift towards using these drugs in more diverse medical fields such as dentistry and ophthalmology.

Local special circumstances: One of the unique aspects of the Irish market is the presence of a strong pharmaceutical industry. Many global pharmaceutical companies have operations in Ireland, which has led to a high level of research and development in the country. This has resulted in the development of new and innovative anti-fibrinolytic drugs that are being used not only in Ireland but also in other markets around the world.

Underlying macroeconomic factors: The growth in the Anti-Fibrinolytic Drugs market in Ireland is also influenced by macroeconomic factors such as government policies and healthcare spending. The Irish government has been investing heavily in the healthcare industry, which has led to an increase in the number of surgeries being performed and a greater demand for anti-fibrinolytic drugs. Additionally, the country's strong economy has allowed for greater healthcare spending, which has further contributed to the growth of this market.Overall, the Anti-Fibrinolytic Drugs market in Ireland is expected to continue its growth trajectory in the coming years. With an increasing demand for these drugs in the healthcare industry and a strong pharmaceutical industry in the country, Ireland is well-positioned to be a major player in this market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.